Mohammad AskarPublic working copy · medical review pending

Cataract and macular disease · 232

Cataract surgery and IOL selection in macular disease

This is a narrative evidence synthesis for adults with cataract and macular disease, focusing on AMD. It combines guidelines, a systematic review and mainly non-randomised primary studies. It is not a new systematic review. The questions concern functional benefit, possible AMD progression, reliable biometry and appropriate IOL optics. Early/intermediate AMD, neovascular AMD (nAMD) and geographic atrophy require separate assessment.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Visually significant cataract can merit surgery in age-related macular degeneration (AMD). The treatable lens component, remaining macular function and patient goals determine the decision. Surgery does not remove a central scotoma caused by atrophy or fibrosis. A contrast-preserving monofocal, optionally toric intraocular lens (IOL) is a pragmatic starting option; spectacle independence should not take priority without weighing visual quality.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Define the benefit and the evidence

Visually significant cataract can merit surgery in age-related macular degeneration (AMD). The treatable lens component, remaining macular function and patient goals determine the decision. Surgery does not remove a central scotoma caused by atrophy or fibrosis. A contrast-preserving monofocal, optionally toric intraocular lens (IOL) is a pragmatic starting option; spectacle independence should not take priority without weighing visual quality. 1 2 3

This is a narrative evidence synthesis for adults with cataract and macular disease, focusing on AMD. It combines guidelines, a systematic review and mainly non-randomised primary studies. It is not a new systematic review. The questions concern functional benefit, possible AMD progression, reliable biometry and appropriate IOL optics. Early/intermediate AMD, neovascular AMD (nAMD) and geographic atrophy require separate assessment. 14

02Assess the macula and explain the prognosis

Assess symptoms, corrected acuity in both eyes, glare, near function, previous injections and everyday goals. Fundus assessment and macular OCT help distinguish active exudation, haemorrhage, atrophy, fibrosis and other causes such as epiretinal membrane or diabetic macular oedema. ESCRS recommends indication-based OCT for AMD. Morphology explains limitations but cannot guarantee a postoperative acuity value. The German AMD guideline emphasises discussing findings, individual expectations and rehabilitation. 1 2

Clinical perspective: Explain which part of the visual haze may arise from the lens and which distortion or central gap is likely to remain. Brighter vision or less glare may be valuable despite little change on an acuity chart. This synthesis cannot predict a specific improvement in walking speed, posture or fall risk for every person with AMD. 14

AREDS2 Report 27 assessed cataract surgery as an observational exposure within a randomised supplement trial: 4,553 eyes of 2,754 participants, followed for up to ten years. Compared with unoperated eyes, no increased late-AMD risk was observed: hazard ratio (HR) 0.96 (95% confidence interval 0.81–1.13) for right eyes and 1.05 (0.89–1.25) for left eyes. Surgery was not randomised; indication bias and residual confounding remain possible. These findings argue against a large additional risk effect, but establish neither zero risk nor protection from surgery. AMD can progress independently. 4

03Check biometry when the macula is elevated

Macular disease may affect fixation, signal quality and identification of the posterior measurement endpoint. An unusual reading does not automatically mean anatomical shortening of the eye. Inspect traces and segmentation, repeat measurements and use additional methods when a discrepancy is plausible; fellow-eye measurements are a consistency check, not an automatic substitute. 14

Nagayama et al. retrospectively studied 30 patients with submacular haemorrhage before/after vitrectomy. In nine cases with haemorrhage height above 1,000 µm or unmeasurable height, absolute deviation from postoperative optical measurement was 0.42 ± 0.33 mm for preoperative optical biometry versus 0.10 ± 0.09 mm for ultrasound. This was a small, selected subgroup, not evidence that ultrasound is superior in every AMD eye. The unverified lecture example of “4 mm/36-D IOL” is not adopted as a rule. 10

04Coordinate nAMD treatment, surgery and review

Plan jointly around disease activity, previous stability, the last and next injection dates, and surgical urgency. Cataract surgery does not replace nAMD treatment. Observational evidence favours a reasonably stable phase but does not define a universal dry period, compulsory simultaneous injection or fixed injection-free interval. 3 11

A Swedish retrospective cohort included 156 patients/168 eyes receiving continuing nAMD treatment. Mean anti-VEGF injection numbers in the six months before/after surgery were 3.4/3.3; visual function improved. Eyes with nAMD onset less than six months earlier were excluded. Without a randomised control arm, the findings cannot establish a universal optimal surgery date. 11

Surgical perspective: Adequate visibility, stable anterior chamber and fluidics, and protection of the capsule, iris and endothelium are core safety goals. Reduce unnecessarily intense or prolonged microscope illumination while maintaining safe visibility. A central stop is not established here as a universal requirement. Include previous injections in the risk history; do not diagnose additional zonulopathy from injection count alone. 3

If the result is unexpectedly poor, assess refraction, cornea, posterior capsule, inflammation, cystoid macular oedema and AMD activity. Postoperative fluid does not automatically indicate nAMD reactivation; findings and course determine interpretation. 14

05Choose IOL properties and the refractive target

Properties can coexist: an IOL may be monofocal, aspheric, toric and blue light-filtering at the same time. “Toric” describes astigmatism correction, not the number of focal points. 1

Clinical perspective: The add-on row describes an individual refractive option, not a recommendation established by comparative AMD studies. Both an additional procedure and later explantation require renewed assessment of expected benefit and risk. 14

ESCRS recommends considering toric IOLs from approximately 1.0 D of regular corneal astigmatism, with stronger evidence above 2.0 D. This is neither an AMD-specific threshold nor a general indication for a secondary toric add-on IOL. The 3 D discussed in the lecture is not a fixed surgical threshold. 1

Clinical perspective: Emmetropia may simplify visual-aid provision. Agree the target with the patient, taking the fellow eye, near habits and low-vision team into account; it is not mandatory for every AMD eye. Consider a second refractive operation only if expected functional benefit justifies the additional procedure. 14

Choose IOL properties and the refractive target
Optics/propertyRole in macular diseaseLimitation
MonofocalPragmatic option when visual quality and contrast preservation take priority.Reading glasses usually needed; does not treat the macula.
AsphericAberration-neutral or spherical-aberration correcting; select according to the eye.AMD-specific additional benefit over other monofocal optics is not robustly established. [3]
Monofocal toricCorrect regular corneal astigmatism, including with limited macular function.Consider topography/tomography, posterior corneal astigmatism, axis and capsular stability. [1]
MultifocalUse cautiously with relevant macular disease because of contrast and dysphotopsia concerns.Relative contraindication, rather than a universal absolute rule established by strong AMD RCTs. [12]
EDOF / enhanced monofocalEvaluate technologies and actual contrast performance separately.Small non-diffractive EDOF series do not establish suitability of all models or AMD stages. [8, 9]
Blue light filterSpectral property; convincing AMD-prevention benefit is unproven.Absence of benefit evidence does not establish harm. [5, 6, 7]
Add-on / duetAn additional sulcus IOL may offer refractive options; it must be designed for that location.Explantability is not risk-free reversibility; robust comparative AMD evidence for this strategy is lacking.

06Read blue-filter evidence by clinical endpoint

The 2018 Cochrane review included 51 randomised studies with over 5,000 eyes overall. Only two studies/131 eyes contributed to the distance-acuity estimate at 6–18 months: mean difference −0.01 logMAR (95% CI −0.03 to 0.02). AMD endpoints were very uncertain; small studies, short follow-up and bias limit conclusions. 5

The Taiwan cohort included 186,591 patients undergoing bilateral surgery, followed for a mean 6.1 years and up to ten years: no apparent AMD advantage after matching. The 2025 Korean cohort compared 21,741 blue-filter with 56,357 clear-IOL recipients, followed for a mean 7.0/6.7 years. Ten-year exudative-AMD incidence was 1.8%/1.7%; adjusted HR 1.12 (95% CI 0.96–1.30). Both are observational studies vulnerable to residual confounding and claims-based diagnoses. 6 7

There is therefore no convincing prevention rationale to prefer a blue filter specifically for AMD. Equally, blanket rejection based on supposedly established night-vision or sleep harm is unsupported. These sources address prevention and clinical function differently; laboratory phototoxicity cannot replace a patient-important endpoint. 14

07Interpret EDOF series and their limits

The second study randomised selection of the analysed eye, not IOL allocation. Improvement compared with a cloudy natural lens does not establish superiority over a monofocal IOL. Carefully selected early/intermediate AMD differs from active nAMD or foveal atrophy. Reliable long-term comparative data on contrast under difficult illumination and progressive AMD remain lacking. 14

Interpret EDOF series and their limits
StudyDesign and findingsCritical appraisal
Thananjeyan et al., 2024 [8]Retrospective; 28 patients/51 eyes at different AMD stages, non-diffractive Vivity; acuity 0.32 to 0.20 logMAR, 27/28 satisfied.No monofocal control; collection over two years is not uniform two-year follow-up. Incremental optical benefit remains uncertain.
Ciarmatori et al., 2026 [9]Prospective single-centre series, early/intermediate AMD; 24/30 patients analysed, 48 operated eyes. At three months, monocular corrected distance acuity 0.30 to 0.00 logMAR; 22/24 satisfied.Four withdrawals/losses, two exclusions after capsule rupture; no comparative IOL arm or late AMD. One eye per patient for monocular analyses; short duration, multiple endpoints and approximate questionnaire scaling.

08Arrange rehabilitation and realistic counselling

The German AMD guideline recommends optical/electronic magnification and supportive reading systems for bilateral visual impairment. Align refractive correction, lighting, magnification and training with actual everyday tasks. 2

Confirms practice: assess the macula before surgery, explain expectations, coordinate nAMD treatment and address residual optical errors. May influence individual decisions: new non-diffractive EDOF data in selected early stages and alternative biometry with large haemorrhage. Insufficient for a general practice change: routine EDOF/add-on recommendations in AMD, protective claims for blue filters or universal refractive targets. 14

What determines the expected benefit of surgery?

Visually significant cataract can merit surgery in age-related macular degeneration (AMD). The treatable lens component, remaining macular function and patient goals determine the decision. Surgery does not remove a central scotoma caused by atrophy or fibrosis. A contrast-preserving monofocal, optionally toric intraocular lens (IOL) is a pragmatic starting option; spectacle independence should not take priority without weighing visual quality.

Which warning signs need prompt assessment?

New distortion, a new central dark spot or sudden loss of vision requires prompt ophthalmic assessment. After surgery or injection, increasing pain, redness and worsening vision require immediate examination.

References and access status

  1. 1
    ESCRS Recommendations for Cataract Surgery. Official recommendations; indication-based OCT, target refraction and toric IOLs.

    Historical 30September 2026: official ESCRS full web recommendations read; no new full-source claim 18November.

  2. 2
    DOG/BVA. Leitlinie Nr. 21: Altersabhängige Makuladegeneration. 11 December 2023.

    Historical 30September 2026: official DOG/BVA AMD PDF11December 2023 read for evaluation/counselling/rehabilitation, not a special-IOL guideline; not newly reread.

  3. 3
    Mehta H. Management of Cataract in Patients with Age-Related Macular Degeneration. J Clin Med. 2021;10:2538. Narrative review. DOI: 10.3390/jcm 10122538.

    Historical 30September 2026 narrative-review context; underlying primary sources separated, not a new systematic review.

  4. 4
    Bhandari S et al. Cataract Surgery and the Risk of Developing Late Age-Related Macular Degeneration: AREDS2 Report Number 27. Ophthalmology. 2022. PMID: 34793832.

    Historical 30September 2026 primary abstract/results; cataract exposure observational within supplement RCT; full report remains a separate task.

  5. 5
    Downie LE, Busija L, Keller PR. Blue-light filtering intraocular lenses (IOLs) for protecting macular health. Cochrane Database Syst Rev. 2018;CD011977. DOI: 10.1002/14651858.CD011977.pub 2.

    Historical 30September 2026 official full Cochrane abstract;51RCTs/>5000 eyes overall but acuity pooling 2 studies/131 eyes; no new full-report access.

  6. 6
  7. 7
    Kim JY et al. Exudative AMD Risk Following Blue Light-Filtering IOL Implantation. Am J Ophthalmol. 2025;279:1–10. DOI: 10.1016/j.ajo.2025.07.007.

    Historical 30September 2026 publisher-hosted full Korean abstract; no full-text-specific bias appraisal.

  8. 8
    Thananjeyan AL et al. Extended Depth-of-Focus Intraocular Lens Implantation in Patients with Age-Related Macular Degeneration: A Pilot Study. Clin Ophthalmol. 2024;18:451–458. DOI: 10.2147/OPTH.S442931.

    Historical 30September 2026 primary abstract and university record; uncontrolled retrospective pilot, not an incremental IOL-effect trial.

  9. 9
  10. 10
  11. 11
    Cataract surgery in neovascular AMD: impact on visual acuity and disease activity. BMC Ophthalmol. 2023;23:276. DOI: 10.1186/s12886-023-03028-7.

    Historical 30September 2026 complete Swedish primary text;156 patients/168 eyes; nonrandomised surgery and onset<6 months excluded.

  12. 12
  13. 13
  14. 14
    Immutable parallel draft PR236, head1d7c31da9eb160773941f3f8cdc509835d6c19f2

    Complete immutable PR236 head1d7c31da9eb160773941f3f8cdc509835d6c19f2 draft captured 18November 2026; historical source claims remain those in legacy-evidence.md, not new primary access.